5CZI

EGFR L858R MUTANT IN COMPLEX WITH A SHC PEPTIDE SUBSTRATE


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.6 Å
  • R-Value Free: 0.225 
  • R-Value Work: 0.183 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

EGF-receptor specificity for phosphotyrosine-primed substrates provides signal integration with Src.

Begley, M.J.Yun, C.H.Gewinner, C.A.Asara, J.M.Johnson, J.L.Coyle, A.J.Eck, M.J.Apostolou, I.Cantley, L.C.

(2015) Nat.Struct.Mol.Biol. 22: 983-990

  • DOI: 10.1038/nsmb.3117
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Aberrant activation of the EGF receptor (EGFR) contributes to many human cancers by activating the Ras-MAPK pathway and other pathways. EGFR signaling is augmented by Src-family kinases, but the mechanism is poorly understood. Here, we show that huma ...

    Aberrant activation of the EGF receptor (EGFR) contributes to many human cancers by activating the Ras-MAPK pathway and other pathways. EGFR signaling is augmented by Src-family kinases, but the mechanism is poorly understood. Here, we show that human EGFR preferentially phosphorylates peptide substrates that are primed by a prior phosphorylation. Using peptides based on the sequence of the adaptor protein Shc1, we show that Src mediates the priming phosphorylation, thus promoting subsequent phosphorylation by EGFR. Importantly, the doubly phosphorylated Shc1 peptide binds more tightly than singly phosphorylated peptide to the Ras activator Grb2; this binding is a key step in activating the Ras-MAPK pathway. Finally, a crystal structure of EGFR in complex with a primed Shc1 peptide reveals the structural basis for EGFR substrate specificity. These results provide a molecular explanation for the integration of Src and EGFR signaling with downstream effectors such as Ras.


    Organizational Affiliation

    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.,Department of Medicine, Weill Cornell Medical College, New York, New York, USA.,Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.,Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.,Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.,Centers for Therapeutic Innovation, Pfizer, Boston, Massachusetts, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Epidermal growth factor receptor
A
331Homo sapiensMutation(s): 1 
Gene Names: EGFR (ERBB, ERBB1, HER1)
EC: 2.7.10.1
Find proteins for P00533 (Homo sapiens)
Go to Gene View: EGFR
Go to UniProtKB:  P00533
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
SHC Peptide substrate
B
9Homo sapiensMutation(s): 0 
Gene Names: SHC1 (SHC, SHCA)
Find proteins for P29353 (Homo sapiens)
Go to Gene View: SHC1
Go to UniProtKB:  P29353
Small Molecules
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
PTR
Query on PTR
B
L-PEPTIDE LINKINGC9 H12 N O6 PTYR
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.6 Å
  • R-Value Free: 0.225 
  • R-Value Work: 0.183 
  • Space Group: I 2 3
Unit Cell:
Length (Å)Angle (°)
a = 143.890α = 90.00
b = 143.890β = 90.00
c = 143.890γ = 90.00
Software Package:
Software NamePurpose
CNSphasing
HKL-2000data reduction
HKL-2000data scaling
PHENIXrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2015-07-31 
  • Released Date: 2015-09-30 
  • Deposition Author(s): Yun, C.H., Eck, M.J.

Revision History 

  • Version 1.0: 2015-09-30
    Type: Initial release
  • Version 1.1: 2015-11-25
    Type: Database references
  • Version 1.2: 2015-12-23
    Type: Database references